Topography Guided LASIK by Different Protocols for Treatment of Astigmatism
NCT ID: NCT03597906
Last Updated: 2020-01-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2018-08-15
2020-01-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
LASIK has been among the highest satisfaction rates of surgical procedures, ranging from 82%-98%. Different ablation profiles have been developed over the years. The purpose of this study is to validate this novel measurement by comparing the visual outcomes when the TMR is used in myopic astigmatic LASIK to using the standard manifest refraction or the Topolyzer measurements alone.
Objectives :
To evaluate the safety, efficacy and predictability of topography-guided myopic LASIK with three different refraction treatment strategies.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Wavefront-guided Versus Wavefront-optimized LASIK for Nearsightedness
NCT01138189
Topography-guided LASIK Surgery
NCT03292419
Topo-guided LASIK and Photorefractive Keratectomy vs Wavefront LASIK and Photorefractive Keratectomy
NCT03075176
Evaluation of Visual Outcomes After Myopic LASIK
NCT00366743
Wavefront-guided vs. Topography-guided LASIK
NCT05588882
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Sample size 60 eyes. surgery:
* 60 eyes of myopic topography-guided LASIK procedures with the same refractive platform (FS200 femtosecond to create a flap between90: 110 μm with diameter 8:9 mm and EX500 excimer lasers) will be randomized for treatment as follows:
* Group A: 20 eyes will be treated using Contoura vision with the standard manifest refraction.
* Group B: 20 eyes will be treated with Contoura vision using the topographic astigmatic power and axis and without change in the spherical power (using the same spherical power as the manifest refraction).
* Group C \[TMR\]: 20 eyes will be treated with Contoura vision using the topographic astigmatic power and axis and modifying the spherical power to obtain the same spherical equivalent as the manifest refraction. This is done by subtracting half of the difference between topographic astigmatic power and the manifest astigmatic power from the spherical power (topography-modified treatment refraction).
* The standard postoperative treatment is combined steroids and antibiotics eye drops 5 times daily for one week ,then three times daily for three days and lubricant eye drops 5 times daily for six months.
Postoperatively, the patients will be examined at 1 week, 1 month and 3 months. All postoperative follow-up visits included measurement of UDVA, CDVA (if indicated) and refraction, besides full ophthalmological examination and performing pentacam and topolyzer after 3 months
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A: Manifest
20 eyes will be treated using Contoura, topography guided ablation vision with the standard manifest refraction.
topography guided ablation
using the data obtained from the topolyzer for correction of refractive errors specially astigmatism we use 3 different treatment protocols
manifest refraction
using for ablation the exact manifest refraction
Group B: partial TMR
20 eyes will be treated with Contoura vision, topography guided ablation using the topographic astigmatic power and axis and without change in the spherical power (using the same spherical power as the manifest refraction).
topography guided ablation
using the data obtained from the topolyzer for correction of refractive errors specially astigmatism we use 3 different treatment protocols
partial topography modified refraction
partial topography modified refraction means changing only cylinder power and axis in the ablation profile
Group C: Full TMR
20 eyes will be treated with Contoura vision, topography guided ablation using the topographic astigmatic power and axis and modifying the spherical power to obtain the same spherical equivalent as the manifest refraction. This is done by subtracting half of the difference between topographic astigmatic power and the manifest astigmatic power from the spherical power (topography-modified treatment refraction).
topography guided ablation
using the data obtained from the topolyzer for correction of refractive errors specially astigmatism we use 3 different treatment protocols
full topography modified refraction
full topography modified refraction means changing both sphere and cylinder power in the ablation profile
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
topography guided ablation
using the data obtained from the topolyzer for correction of refractive errors specially astigmatism we use 3 different treatment protocols
manifest refraction
using for ablation the exact manifest refraction
full topography modified refraction
full topography modified refraction means changing both sphere and cylinder power in the ablation profile
partial topography modified refraction
partial topography modified refraction means changing only cylinder power and axis in the ablation profile
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Valid Topolyzer maps (at least four out of eight right maps with green analyzed area and the registration box is green).
Exclusion Criteria
2. Glaucomatous patients.
3. Patients with keratoconus.
4. Patients with pervious refractive surgery.
5. History of previous ocular trauma or surgery.
6. History of recent herpetic ulcer or viral keratitis.
7. Basement membrane disease, history of recurrent corneal erosions.
8. Sicca syndrome, dry eye.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fayrouz Aboalazayem
the principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohmed Hosny, MD
Role: STUDY_DIRECTOR
Cairo University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kasr Alainy
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N-18-2018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.